Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an …

Acute myeloid leukemia (AML) can develop after an antecedent myeloid malignancy (secondary
AML [s-AML]), after leukemogenic therapy (therapy-related AML [t-AML]), or without an …

Background Elderly patients with primary acute myelogenous leukemia (AML) are less likely
to enter remission than younger adults, in part because of a higher mortality rate related to …

Advances in our understanding of the pathophysiology of acute myeloid leukemia (AML)
have not yet led to major improvements in disease-free and overall survival of adults with this …

The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

Purpose: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from
bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. …

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-…

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and
safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly …

Background Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to
10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted…